Thermo Fisher Scientific Inc. has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.   “Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally,” said Marc N. Casper, chairman, president and chief executive officer, Thermo Fisher Scientific. “Investments in state-of-th...